133 related articles for article (PubMed ID: 24128108)
1. [McHutchison's legacy and adherence in hepatitis C].
Ibarra Barrueta O
Farm Hosp; 2013; 37(5):424-5. PubMed ID: 24128108
[No Abstract] [Full Text] [Related]
2. A modified ribavirin-free interferon therapy with boceprevir in post-liver transplant recurrent hepatitis C.
Maticic M; Luznik Z; Stepec S; Popovic P; Snedec N; Poljak M; Stanisavljevic D
J Clin Gastroenterol; 2014; 48(5):464-5. PubMed ID: 24275712
[No Abstract] [Full Text] [Related]
3. PEG-IFN, RBV dosing during chronic HCV re-treatment.
Highleyman L
IAPAC Mon; 2007 Feb; 13(2):55. PubMed ID: 17948601
[No Abstract] [Full Text] [Related]
4. Impact of occult hepatitis B virus infection or hepatitis B virus DNA integration on efficacy of chronic hepatitis C treatment with peginterferon and ribavirin: where are we?
Hu KQ; Zhang YY
J Clin Gastroenterol; 2014 Jan; 48(1):3-5. PubMed ID: 24045272
[No Abstract] [Full Text] [Related]
5. Randomized clinical trial comparing high versus standard dose of ribavirin plus peginterferon alfa-2a in hepatitis C genotype 3 and high viral load. Dargen-3 study.
Fernández-Rodríguez CM; Morillas RM; Masnou H; Navarro JM; Bárcena R; González JM; Martín-Martín L; Poyato A; Miquel-Planas M; Jorquera F; Casanovas T; Salmerón J; Calleja JL; Solà R; Alonso S; Planas R; Romero-Gomez M
Gastroenterol Hepatol; 2014 Jan; 37(1):1-8. PubMed ID: 24360571
[TBL] [Abstract][Full Text] [Related]
6. Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection.
Lagging M; Langeland N; Pedersen C; Färkkilä M; Buhl MR; Mørch K; Dhillon AP; Alsiö A; Hellstrand K; Westin J; Christensen P; Leutscher P; Norkrans G;
Hepatology; 2008 Aug; 48(2):695. PubMed ID: 18666232
[No Abstract] [Full Text] [Related]
7. [Advance in the management of the difficult-to-treat patients with chronic hepatitis C].
Xie Y; Li MH
Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):484-6. PubMed ID: 19912677
[No Abstract] [Full Text] [Related]
8. [Individualization of antiviral treatment of chronic hepatitis].
Konstantinov DIu; Konstantinova EA; Strebkova EA; Popova LL; Suzdal'tsev AA
Eksp Klin Gastroenterol; 2013; (6):29-34. PubMed ID: 24772857
[No Abstract] [Full Text] [Related]
9. Retinal vein thrombosis associated with peginterferon alpha 2b plus ribavirin in a chronic hepatitis C patient.
Such Díaz A; Barrueco N; Esteban Alba C; Escobar Rodríguez I
Farm Hosp; 2011; 35(2):93-4. PubMed ID: 20615736
[No Abstract] [Full Text] [Related]
10. ADVANCE study begins enrollment.
AIDS Patient Care STDS; 2008 Apr; 22(4):345. PubMed ID: 18422463
[No Abstract] [Full Text] [Related]
11. [The study of optimal treatment in patients with refractory chronic hepatitis C].
Chen XY; Zhang YH
Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):488-9. PubMed ID: 19912679
[No Abstract] [Full Text] [Related]
12. [Cutaneous necrosis due to injection of interferon-alpha 2b in a patient with chronic hepatitis C].
Castellanos González M; Pérez Carreras M; Muñoz Gómez R; Castellano Tortajada G
Gastroenterol Hepatol; 2011 Oct; 34(8):584-5. PubMed ID: 21641684
[No Abstract] [Full Text] [Related]
13. [Possible telaprevir-induced pancreatitis. A case study].
Selvi Sabater P; Espuny Miró A; Muñoz Bertrán ED; Plaza Aniorte J
Farm Hosp; 2013; 37(3):269-70. PubMed ID: 23789806
[No Abstract] [Full Text] [Related]
14. Efficacy and safety of peginterferon α-2a (40 KD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern Europe.
Urbanek P; Oltman M; Ivanovski L; Rehák V; Messinger D; Tietz A; Husa P
Eur J Gastroenterol Hepatol; 2011 Nov; 23(11):1004-10. PubMed ID: 21904204
[TBL] [Abstract][Full Text] [Related]
15. [Difficult-to-treat patient with chronic hepatitis C: a challenge in clinical practice].
Dou XG
Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):486-7. PubMed ID: 19912678
[No Abstract] [Full Text] [Related]
16. [Antiviral therapy of patients with chronic hepatitis C with normal level of aminotransferases].
Lopukhova NL
Eksp Klin Gastroenterol; 2007; (4):146-52. PubMed ID: 18409502
[No Abstract] [Full Text] [Related]
17. [High dose repeat therapy in previously treated patients with chronic hepatitis C].
Hoepffner N; Paul KA; Nikodem AB; Teuber G
Dtsch Med Wochenschr; 2006 Mar; 131(11):543-4. PubMed ID: 16538557
[No Abstract] [Full Text] [Related]
18. Pushing the treatment envelope for chronic hepatitis C--is more necessarily better?
Lutchman G; Ghany M
Hepatology; 2005 Feb; 41(2):234-6. PubMed ID: 15657958
[No Abstract] [Full Text] [Related]
19. The treatment of viral hepatitis, present and future.
Rodés J
J Hepatobiliary Pancreat Surg; 2003; 10(2):163-7. PubMed ID: 14505150
[No Abstract] [Full Text] [Related]
20. Ribavirin in chronic hepatitis C: past and future.
Loustaud-Ratti V; Rousseau A; Marquet P; Denis F; Alain S
Expert Rev Anti Infect Ther; 2009 Apr; 7(3):249-53. PubMed ID: 19344238
[No Abstract] [Full Text] [Related]
[Next] [New Search]
